ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,743.58
      0.84%
      US Tech 100
      19,509.20
      1.17%
      Dow Jones
      42,061.90
      0.26%
      Brent Oil
      77.30
      -4.49%
      Bitcoin
      62,120.43
      -0.16%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. IO Biotech Inc (IOBT) Quote

      IO Biotech Inc

      IO Biotech Inc (IOBT)

      NASDAQ
      1.10
      0.03
      ( 2.80% )
      Updated: 14:17:37
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      1.10
      Bid
      1.10
      Ask
      1.11
      Volume
      54,131
      1.05 Day's Range 1.12
      0.7327 52 Week Range 2.098
      Market Cap
      72.469M
      Previous Close
      1.07
      Open
      1.11
      Last Trade
      100
      @
      1.1
      Last Trade Time
      14:17:37
      Financial Volume
      $ 58,985
      VWAP
      1.0897
      Average Volume (3m)
      464,258
      Shares Outstanding
      65,880,914
      Dividend Yield
      -
      PE Ratio
      -0.84
      Earnings Per Share (EPS)
      -1.31
      Revenue
      -
      Net Profit
      -86.08M

      About IO Biotech Inc

      IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced imm... IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.iobiotech.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      IO Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IOBT. The last closing price for IO Biotech was $1.07. Over the last year, IO Biotech shares have traded in a share price range of $ 0.7327 to $ 2.098.

      IO Biotech currently has 65,880,914 shares outstanding. The market capitalization of IO Biotech is $70.49 million. IO Biotech has a price to earnings ratio (PE ratio) of -0.84.

      Ask ADVFN Intelligence (AI)

      IOBT Latest News

      More News

      FeaturedCBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024

      7 hours ago

      IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

      NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines...

      October 04 2024
      GlobeNewswire Inc.

      IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

      -- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety...

      September 14 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      August 30 2024
      Edgar (US Regulatory)

      IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

      - Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety...

      August 30 2024
      GlobeNewswire Inc.

      IO Biotech Announces Participation in Upcoming Investor Conferences

      NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

      August 26 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 13 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 13 2024
      Edgar (US Regulatory)

      IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

      Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine...

      August 13 2024
      GlobeNewswire Inc.

      IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

      NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

      July 25 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.043.773584905661.061.19121.011487171.10149647CS
      40.18999920.87898804510.9100011.420.73278577491.00338824CS
      12-0.32-22.53521126761.421.730.73274642581.11504756CS
      26-0.58-34.52380952381.681.790.73272698621.1618702CS
      52-0.25-18.51851851851.352.0980.73272048171.26385217CS
      156-14.9-93.1251617.880.73271293762.6686456CS
      260-14.9-93.1251617.880.73271293762.6686456CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      LASELaser Photonics Corporation
      $ 8.64
      (100.00%)
      		51.45M
      OTRKOntrak Inc
      $ 2.815
      (54.67%)
      		95.67M
      PDYNPalladyne AI Corporation
      $ 2.7307
      (45.25%)
      		18.47M
      TURBTurbo Energy SA
      $ 2.16
      (40.26%)
      		1.54M
      PRTGPortage Biotech Inc
      $ 7.24
      (32.36%)
      		360.88k
      VINCVincerx Inc
      $ 0.4622
      (-33.78%)
      		7.61M
      SOBRSOBR Safe Inc
      $ 7.09
      (-29.80%)
      		885.17k
      ZJKZJK Industrial Company Ltd
      $ 4.9248
      (-27.58%)
      		342.74k
      DBGIDigital Brands Group Inc
      $ 0.205
      (-27.56%)
      		3.21M
      CETXCemtrex Inc
      $ 1.005
      (-26.64%)
      		9.7M
      AGRIAgriFORCE Growing Systems Ltd
      $ 0.0555
      (15.63%)
      		315.74M
      NVDANVIDIA Corporation
      $ 132.37
      (3.64%)
      		201.53M
      XPONExpion360 Inc
      $ 0.0317
      (-7.31%)
      		187.71M
      VERBVerb Technology Company Inc
      $ 0.0459
      (9.29%)
      		128.92M
      ALCEAlternus Clean Energy Inc
      $ 0.1494
      (-0.33%)
      		124.98M

      IOBT Discussion

      View Posts
      Monksdream Monksdream 23 hours ago
      IOBT under $2


      👍️0
      glenn1919 glenn1919 4 days ago
      IOBT.................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783
      👍️0
      axelvento axelvento 4 days ago
      IOBiotech
      is pleased to announce that it will be presenting two posters at the SITC 2024 Annual Meeting.

      The first poster presentation contains updated and expanded data from the complete cohort (n=31) from the first line (1L) cohort of patients with PD-L1 high metastatic non-small cell lung cancer (NSCLC) in our Phase 2 basket trial of investigational IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy. The second poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.

      We look forward to sharing these exciting data at the meeting which takes place in Houston from November 6-10, 2024. See full details here:

      https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Two-Poster-Presentations-at-the-Society-for-Immunotherapy-of-Cancers-SITC-39th-Annual-Meeting/default.aspx
      👍️0
      glenn1919 glenn1919 3 weeks ago
      iobt................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 4 weeks ago
      IOBT new 52 week low
      https://investorshub.advfn.com/uimage/uploads/2024/9/12/fmdniIMG_1694.gif
      👍️0
      Monksdream Monksdream 1 month ago
      IOBT under $2
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      starting to run into the readout
      Lead investigator and advisors that helped BMS in making ipi+nivo the new SOC --- They now work on this. Cancer vaccines back in fashion.
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      Sorry for the late reply, im not yet fully familiar with this platform.
      The SOC for advanced melanoma is Ipi + Nivo which is neither very helpful nor very safe. Hence "the bar is hanging low" here.
      👍️0
      Monksdream Monksdream 3 months ago
      IOBT
      👍️0
      stock1ace1 stock1ace1 3 months ago
      Standard of care …
      👍️0
      Monksdream Monksdream 3 months ago
      IOBT under $2
      👍️0
      ralfito ralfito 4 months ago
      For us dummies, can you define SOC in this context? Thanks.
      👍️0
      PonkenPlonken PonkenPlonken 4 months ago
      CEO made it pretty clear numerous times at Jefferies IMO
      they will become the SOC, not only in advanced melanoma but in all stages.
      They also think their platform can be used for non-cancer indications.

      2 Birds in the hand and many more in the bush$$$
      👍️0
      PonkenPlonken PonkenPlonken 4 months ago
      https://www.youtu be.com/watch?v=OvC-86SN9Ao&ab_channel=VJOncology

      australian KOL on IOBT

      many things pointing at it becoming the SOC one day...
      👍️0
      axelvento axelvento 4 months ago
      golden cross MA50 MA200
      👍️0
      axelvento axelvento 5 months ago
      a planned interim analysis of ORR will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024 and, if supportive, we believe could allow for submission of a BLA for accelerated approval in the US.
      Cash and cash equivalents as of March 31, 2024 were $118.0 million, compared to $143.2 million at December 31, 2023. During the three months ended March 31, 2024, the company used cash, cash equivalents and restricted cash of $24.9 million. The increase in cash use was primarily driven by milestone payments and payment of other accrued expenses associated with clinical trials, as well as the payment of year-end bonuses. The company continues to expect that it will have sufficient cash to run the company into the fourth quarter of 2025.
      👍️0
      axelvento axelvento 5 months ago
      Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee
      Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors
      Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025

      https://www.biopharmcatalyst.com/company/IOBT/news/190095
      👍️0
      axelvento axelvento 5 months ago
      https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Abstract-Accepted-for-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspx
      👍️0
      axelvento axelvento 6 months ago
      IO Biotech was founded in 2014 and just 10 years into the journey we are in a pivotal phase III trial I think that’s quite fast
      👍️0
      axelvento axelvento 6 months ago
      next catalyst-In November 2023, the company completed enrollment of 380 patients in its pivotal Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in advanced melanoma. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS). The PFS analysis is event-driven and will be conducted when 226 events have occurred in the trial, which the company estimates will take place in the second half of 2025. Additionally, a planned interim analysis of overall response rate (ORR) will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024.
      👍️0
      Monksdream Monksdream 7 months ago
      IOBT under $2
      👍️0
      Monksdream Monksdream 8 months ago
      IOBT under $2
      👍️0
      Monksdream Monksdream 11 months ago
      IOBT new 52 week low
      👍️0
      Monksdream Monksdream 12 months ago
      IOBT new 52 week low
      👍️0
      Monksdream Monksdream 1 year ago
      IOBT ubder $2
      👍️0
      AJ Freely AJ Freely 1 year ago
      $IOBT - 👆Up 1.8% Pre-Market/ Current Price $2.00
      Announces $75 Million Private Placement Financing
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      kzivann kzivann 1 year ago
      Extremely heavy volume on good news. PPS down . Lower this AM. Watching

      IOBT
      👍️0
      Phosphene Phosphene 2 years ago
      IO Biotech’s (NASDAQ:IOBT ) lock-up period is set to end on Wednesday, May 4th.

      https://www.defenseworld.net/2022/04/27/io-biotech-inc-s-lock-up-period-set-to-end-on-may-4th-nasdaqiobt.html
      👍️0
      conix conix 3 years ago
      Bitoechs are waking up ---like they did last year.

      I shopped for a number of sold out biotechs in December and picked and chose a number of sold out biotechs.

      IOBT --I missed. But there are legs here. I have done well on four of my picks. Still waiting on two.

      Time will tell.
      👍️0
      Phosphene Phosphene 3 years ago
      IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

      IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types

      https://www.globenewswire.com/news-release/2021/12/06/2346557/0/en/IO-Biotech-Announces-Third-Clinical-Collaboration-with-Merck-to-Evaluate-IO102-IO103-in-Combination-With-KEYTRUDA-pembrolizumab-as-First-Line-Treatment-in-a-Phase-2-Multi-Arm-Baske.html

      👍️0
      Eggplant Eggplant 3 years ago
      What happened? IPO at $14/sh four weeks ago, and the stock has nearly folded in half. No news, and the only sellers should be the IPO buyers, right? Mystery.
      👍️0
      Work Harder Work Harder 3 years ago
      I was right on the 7

      for now

      Yu tell wifeie

      I appreciate her time

      :}
      👍️0
      Phosphene Phosphene 3 years ago
      Did Sunstone/Verland recoup initial seed?









      👍️0
      Staypositive1 Staypositive1 3 years ago
      might wait till .035...lol
      👍️0
      Phosphene Phosphene 3 years ago
      IO Biotech begins trading on Nasdaq Global Market today.

      IPO pps is $14.

      Thu, November 4, 2021, 11:52 PM.

      https://finance.yahoo.com/news/io-biotech-inc-announces-pricing-035200314.html?fr=sycsrp_catchall

      Sunstone and Novo Holdings involved.
      👍️0
      Phosphene Phosphene 3 years ago
      EXPLORATORY PROJECT TO COMPARE IO BIOTECH ANTIGENS LINKED TO MYMETICS’ (MYMX) VIROSOMES IN A PRECLINICAL TUMOR MODEL

      https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/


      IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

      https://www.prnewswire.com/news-releases/io-biotech-announces-clinical-collaboration-with-msd-to-evaluate-io102-io103-with-keytruda-pembrolizumab-as-first-line-treatment-in-metastatic-melanoma-patients-in-a-phase-3-trial-301375679.html
      👍️0
      Phosphene Phosphene 3 years ago
      Denmark's IO Biotech seeks $110M+ in Nasdaq debut.

      https://pitchbook.com/newsletter/denmarks-io-biotech-seeks-110m-in-nasdaq-debut

      https://www.fiercebiotech.com/biotech/io-biotech-raises-155m-to-trial-ido-and-pd-l1-cancer-vaccines

      https://www.iobiotech.com/

      The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma

      https://www.firstwordpharma.com/node/1783725?tsid=17
      👍️0

      Your Recent History

      NASDAQ
      IOBT
      IO Biotech
      Delayed Upgrade Clock